Novartis Acquires Kate Therapeutics for Gene Therapy
Novartis acquires Kate Therapeutics to advance gene therapies for neuromuscular diseases.
Novartis has acquired Kate Therapeutics, a company focused on gene therapies for inherited neuromuscular diseases, in a deal worth up to $1.1 billion. This acquisition includes preclinical programs targeting Duchenne muscular dystrophy, facioscapulohumeral dystrophy, and myotonic dystrophy type 1. Kate’s DELIVER platform, which enhances the precision of gene therapy delivery using evolved AAV capsids, aligns with Novartis’ commitment to addressing unmet needs in neuromuscular disorders.
With the addition of Kate’s cutting-edge technology, Novartis strengthens its position in gene therapy and neuroscience innovation, opening new avenues for safer and more effective treatments for these challenging genetic diseases.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
Altro da Pharma News
Tutti gli articoli →
Medicus Pharma presenta all’FDA il protocollo di fase 2b/3 per Teverelix
Fresenius Kabi Riceve una Lettera di Richiamo dalla FDA dopo Fallimenti nelle Indagini sul Processo Asettico presso lo Stabilimento di Melrose Park
Discussion